Skip to main content

Cencora Inc. Value Stock - Dividend - Research Selection

Amerisourcebergen

ISIN: US03073E1055 , WKN: 766149

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment provides pharmaceutical distribution and other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers. The company\'s Other segment provides commercialization support services, including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers; specialty transportation and logistics services for the biopharmaceutical industry; and animal health care products. It markets its products and services through independent sales forces and marketing organizations. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Cencora (COR) Valuation Check After Strong Multi‑Year Shareholder Returns

2026-02-12
Cencora (COR) has moved higher recently. With the shares last closing at $365.70, many investors are revisiting the pharmaceutical distributor’s long term return profile and current valuation signals. See our latest analysis for Cencora. The recent 1 day share price return of 1.58% and 7 day share price return of 10.83% sit against a far stronger long term picture, with 1 year total shareholder return of 51.29% and 5 year total shareholder return of 265.50%, suggesting momentum has been...

1 Momentum Stock with Impressive Fundamentals and 2 We Question

2026-02-12
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

Cencora Inc. stock outperforms competitors on strong trading day

2026-02-11
Cencora Inc. stock outperforms competitors on strong trading day

5 Revealing Analyst Questions From Cencora’s Q4 Earnings Call

2026-02-11
Cencora's fourth quarter was marked by a negative market reaction, as revenue missed Wall Street’s expectations despite year-over-year growth. Management attributed performance to continued growth in its U.S. healthcare solutions, particularly specialty pharmaceuticals and new contributions from recent acquisitions. CEO Robert Mauch emphasized the impact of enhanced operational capabilities and highlighted the integration of Retina Consultants of America (RCA) and the completion of the OneOncolo

Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056

2026-02-10
CONSHOHOCKEN, Pa., February 10, 2026--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the "2029 Notes"), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the "2030 Notes"), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the "2033 Notes"), $1.0 billion aggregate principal amount of its 4.900% Senior Notes due Februar

JP Morgan Maintains Overweight on Cencora, Raises Price Target to $419

2026-02-10
JP Morgan analyst Lisa Gill maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $417 to $419.

Beyond The Numbers: 6 Analysts Discuss Cencora Stock

2026-02-10

What Are Wall Street Analysts' Target Price for Cencora Stock?

2026-02-10
Cencora has consistently outperformed the broader market over the past year, and analysts are maintaining a strongly bullish outlook on the company’s growth and earnings potential.

Wells Fargo Maintains Overweight on Cencora, Raises Price Target to $429

2026-02-10
Wells Fargo analyst Stephen Baxter maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $405 to $429.

Chief Executives for Corporate Purpose Announces Covista Chairman and CEO Steve Beard, Cencora Inc. Former Executive Chair Steven H. Collis, and Ann Fairchild, interim President and CEO of Siemens USA Joining Board of Directors

2026-02-09
NEW YORK CITY, NY / ACCESS Newswire / February 9, 2026 / Chief Executives for Corporate Purpose® (CECP) announced today that three distinguished executives will join the organization's Board of Directors: Steve Beard, Chairman and CEO of Covista, ...